JP2000507216A - PPAR―γに対するアゴニスト活性を有する置換4―ヒドロキシフェニルアルカン酸誘導体 - Google Patents
PPAR―γに対するアゴニスト活性を有する置換4―ヒドロキシフェニルアルカン酸誘導体Info
- Publication number
- JP2000507216A JP2000507216A JP9530586A JP53058697A JP2000507216A JP 2000507216 A JP2000507216 A JP 2000507216A JP 9530586 A JP9530586 A JP 9530586A JP 53058697 A JP53058697 A JP 53058697A JP 2000507216 A JP2000507216 A JP 2000507216A
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- ethoxy
- methyl
- propionic acid
- benzoylphenylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 下記式(I)を有する化合物: 〔上記式中 Aは: (i)フェニル〔そのフェニルは1以上のハロゲン原子、C1-6アルキル、 C1-3アルコキシ、C1-3フルオロアルコキシ、ニトリルまたは ‐NR7R8(R7およびR8は独立して水素またはC1-3アルキルである) で場合により置換されている〕 (ii)酸素、窒素および硫黄から選択される少くとも1つのヘテロ原子を 含む5または6員ヘテロ環式基、および ヘテロ環式基を表し、二環式環は環Cの環原子で基Bに結合されている) からなる群より選択される; Bは: (iv)C1ー6アルキレン (v)‐MC1-6アルキレンまたはC1-6アルキレンMC1-6アルキレン(Mは O、Sまたは-NR2であり、R2は水素またはC1-3アルキルを表す) (vi)少くとも1つの窒素ヘテロ原子と、場合により酸素、窒素および硫黄 から選択される少くとも1つの別なヘテロ原子とを含む、場合により C1-3アルキルで置換された、5または6員ヘテロ環式基、および (Vii)Het‐C1-6アルキレン(Hetは前記(vi)で定義されたような ヘテロ環式基を表す) からなる群より選択される; AlkはC1-3アルキレンを表す; R1は水素またはC1-3アルキルを表す; Zは: (viii)‐(C1-3アルキレン)フェニル(フェニルは1以上のハロゲン原子で 場合により置換されている)、および (ix)‐NR3R4〔R3は水素またはC1-3アルキルを表し、R4は ‐Y‐(C=O)‐T‐R5または‐Y‐(CH(OH))‐T‐R5を 表す;上記式中: (a)Yは結合、C1-6アルキレン、C2-6アルケニレン、C4-6シクロ アルキレンもしくはシクロアルケニレン、前記(vi)で定義された ようなヘテロ環式基、または1以上のC1-3アルキル基および/または 1以上のハロゲン原子で場合により置換されたフェニルを表す; (b)Tは結合、C1-3アルキレンオキシ、‐O‐または‐N(R6)‐ (R6は水素またはC1-3アルキルを表す)を表す; (c)R5はC1-6アルキル、C4-6シクロアルキルもしくはシクロ アルケニル、フェニル〔1以上のハロゲン原子、C1-3アルキル、 C1-3アルコキシ基、C0-3アルキレンNR9R10(各R9および R10は独立して水素、C1-3アルキル、‐SO2C1-3アルキル、 ‐CO2C1-3アルキル、‐SO2NHC1-3アルキルである)、 C0-3アルキレンCO2H、C0-3アルキレンCO2C1-3アルキル または‐OCH2C(O)NH2で場合により置換されている〕、前記 (ii)で定義されたような5または6員ヘテロ環式基、二環式縮合環 少くとも1つのヘテロ原子を含み、場合により(=O)で置換された 5または6員ヘテロ環式基を表し、二環式環は環Dの環原子でTに結合 されている)または‐C1-6アルキレンMR11(MはO、Sまたは ‐NR2であり、R2およびR11は独立して水素または C1-3アルキルを表す)を表す〕 からなる群より選択される〕 またはその互変異性体、および/またはその薬学上許容される塩または溶媒和物 。 2. 5または6員ヘテロ環式基の各々が、置換または非置換イミダゾリジニ ル、ピペリジル、ピペラジニル、ピロリジニル、モルホリニル、ピリジル、ピリ ダジニル、ピリミジニル、ピラジニル、ピロリル、ピラゾリル、イミダゾリル、 ピラニル、フリル、チエニル、オキサゾリル、イソキサゾリル、オキサジアゾリ ル、チアゾリル、チアジアゾリル、トリアゾリルまたはテトラゾリルからなる群 より独立して選択される、請求項1に記載の化合物。 3. Aがフェニル、ピリジル、ピペラジニルまたはベンゾゾリルを表し、そ れらはいずれも1以上のC1-3アルキルで場合により置換されている、請求項1 または2に記載の化合物。 4. Aがフェニル、ピペラジニルまたはピリジルを表す、請求項3に記載の 化合物。 5. BがC1-3アルキレン、‐N(CH3)C1-3アルキレンまたはHet‐ C1-6アルキレン(Hetは、少くとも1つの窒素原子と、場合により酸素およ び硫黄から選択される少くとも1つの別なヘテロ原子とを含む、C1-3アルキル で置換されたまたは非置換の、5員ヘテロ環式基を表す)を表す、請求項1〜4 のいずれか一項に記載の化合物。 6. Bが‐N(CH3)(CH2)2、オキサゾリル‐C1-6アルキレン(オキ サゾリルは場合によりC1-3アルキルで置換されている)、または場合によりC1 -3 アルキルで置換されたチアゾリルを表す、請求項5に記載の化合物。 7. Alkがメチレンを表す、請求項1〜6のいずれか一項に記載の化合物 。 8. R1が水素、メチルまたはエチルを表す、請求項1〜7のいずれか一項 に記載の化合物。 9. R1が水素である、請求項8に記載の化合物。 10. ZがNR3R4を表し、R3およびR4が請求項1に記載されたとおりで ある、請求項1〜9のいずれか一項に記載の化合物。 11. R3が水素である、請求項10に記載の化合物。 12. R4が‐Y‐(C=O)‐T‐R5を表し、R5が請求項1に記載され たとおりである、請求項10または11に記載の化合物。 13. Yが、1以上のC1-3アルキル基および/または1以上のハロゲン原 子で場合により置換されたフェニルである、請求項8に記載の化合物。 14. Tが結合または‐O‐である、請求項9に記載の化合物。 15. R5がC1ー3アルキルまたは(1以上のハロゲン原子または1以上のC1-3 アルキル基で場合により置換された)フェニルを表す、請求項12、13ま たは14に記載の化合物。 16. NHおよび(C=O)は(フェニルである)Y上で互いにオルト位に あり、Tは結合または‐O‐であり、R5はC1-6アルキルまたは〔1以上のハロ ゲン原子、C1-3アルキル、C1-3アルコキシ基、C0-3アルキレンNR9R10(各 R9およびR10は独立して水素、C1-3アルキル、‐SO2C1-3アルキル、‐CO2 C1-3アルキル、‐SO2NHC1-3アルキルである)、C0-3アルキレンCO2H 、C0-3アルキレンCO2C1-3アルキルまたは‐OCH2C(O)NH2で場合に より置換された〕フェニルである、 請求項10に記載の化合物。 17. R4が を表す(上記式中R13はフェニルまたはOCH3である)、請求項15または1 6に記載の化合物。 18. 下記式(Ia)で表される:(上記式中AおよびBは請求項1に記載されたとおりであり、Arはフェニル、 あるいは酸素、窒素および硫黄から選択される少くとも1つのヘテロ原子を含む 5または6員ヘテロアリール基を表す)、請求項1に記載の化合物。 19. 下記式(I)を有する請求項1に記載の化合物: 〔上記式中 Aは: (i)1以上のハロゲン原子で場合により置換されたフェニル (ii)酸素、窒素および硫黄から選択される少くとも1つのヘテロ原子を 含む5または6員ヘテロ環式基、および ヘテロ環式基を表し、二環式環は環Cの環原子で基Bに結合されている) からなる群より選択される; Bは: (iv)C1-6アルキレン (v)‐NR2C1-6アルキレン(R2は水素またはC1-3アルキルを表す) (vi)少くとも1つの窒素ヘテロ原子と、場合により酸素、窒素および硫黄 から選択される少くとも1つの別なヘテロ原子とを含み、場合により C1-3アルキルで置換された、5または6員ヘテロ環式基、および (vii)Het‐C1ー6アルキレン(Hetは前記(vi)で定義されたような ヘテロ環式基を表す) からなる群より選択される; AlkはC1-3アルキレンを表す; R1は水素またはC1ー3アルキルを表す; Zは: (viii)‐(C1ー3アルキレン)フェニル(フェニルは1以上のハロゲン原子で 場合により置換されている)、および (ix)‐NR3R4〔R3は水素またはC1ー3アルキルを表し、R4は ‐Y‐(C=O)‐T‐R5または‐Y‐(CH(OH))‐T‐R5を 表す;上記式中: (a)Yは結合、C1-6アルキレン、C2-6アルケニレン、C4-6シクロ アルキレンもしくはシクロアルケニレン、前記(vi)で定義された ようなヘテロ環式基、または1以上のC1-3アルキル基および/または 1以上のハロゲン原子で場合により置換されたフェニルを表す; (b)Tは結合、C1ー3アルキレンオキシ、‐O‐または‐N(R6)‐ (R6は水素またはC1-3アルキルを表す)を表す; (c)R5はC1-6アルキル、C4-6シクロアルキルもしくはシクロ アルケニル、1以上のハロゲン原子または1以上のC1-3アルキル基で 場合により置換されたフェニル、前記(ii)で定義されたような (環Dは、酸素、窒素および硫黄から選択される少くとも1つの ヘテロ原子を含み、場合により(=O)で置換された5または6員 ヘテロ環式基を表し、二環式環は環Dの環原子でTに結合されている) を表す〕 からなる群より選択される〕 またはその互変異性体、および/またはその薬学上許容される塩または溶媒和物 。 20. 3‐(4‐ベンジルオキシフェニル)‐2(S)‐(1‐メチル‐3 ‐オキソ‐3‐フェニルプロペニルアミノ)プロピオン酸ジシクロヘキシルアミ ン塩 3‐(4‐ベンジルオキシフェニル)‐2(S)‐(1‐メチル‐3‐オキソ ‐3‐フェニルプロペニルアミノ)プロピオン酸メチルエステル 2(S)‐(2‐ベンゾイルシクロヘキサ‐1‐エニルアミノ)‐3‐(4‐ ベンジルオキシフェニル)プロピオン酸ジシクロヘキシルアミン塩 2‐(2‐ベンゾイルフェニルアミノ)‐3‐(4‐ベンジルオキシフェニル )プロパン酸 3‐(4‐ベンジルオキシフェニル)‐2‐(2‐べンジルオキシフェニルア ミノ)プロピオン酸メチルエステル 3‐(4‐ベンジルオキシフェニル)‐2‐(フェニルカルバモイルフェニル アミノ)プロピオン酸メチルエステル 3‐(4‐ベンジルオキシフェニル)‐2‐〔2‐(ピペリジン‐1‐カルボ ニル)フェニルアミノ〕プロピオン酸メチルエステル 2‐(3‐ベンゾイルチオフェン‐2‐イルアミノ)‐3‐(4‐ベンジルオ キシフェニル)プロピオン酸 2‐(2‐ベンゾイルチオフェン‐3‐イルアミノ)‐3‐(4‐ベンジルオ キシフェニル)プロピオン酸 3‐(4‐ベンジルオキシフェニル)‐2(S)‐〔(4‐オキソ‐4H‐ク ロメン‐3‐カルボニル)アミノ〕プロピオン酸メチルエステル 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(メチルピリジン ‐2‐イルアミノ)エトキシ〕フェニル〕プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(メチルピ リジン‐2‐イルアミノ)エトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(メチルピリジン ‐2‐イルアミノ)エトキシ〕フェニル〕プロピオン酸エチルエステル 2‐(1‐メチル‐3‐オキソ‐3‐フェニルプロペニルアミノ)‐3‐〔4 ‐〔2‐(メチルピリジン‐2‐イルアミノ)エトキシ〕フェニル〕プロピオン 酸ジシクロヘキシルアミン塩 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(2‐ベンゾイルフェニルアミノ)プロピオン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(2‐ベンゾイルフェニルアミノ)プロピオン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2(S)‐(1‐メチル‐3‐オキソ‐3‐フェニルプロペニルア ミノ)プロピオン酸ジシクロヘキシルアミン塩 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2(S)‐〔3‐(3‐ヨードフェニル)‐1‐メチル‐3‐オキ ソプロペニルアミノ〕プロピオン酸ジシクロヘキシルアミン塩 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(2‐ベンゾイル‐4‐メチルフェニルアミノ)プロピオン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(2‐ベンゾイル‐4‐クロロフェニルアミノ)プロピオン酸 3‐〔4‐(1‐ベンゾオキサゾール‐2‐イルピロリジン‐3‐イルオキシ )フェニル〕‐2‐(2‐ベンゾイルフェニルアミノ)プロピオン酸 3‐〔4‐(1‐ベンゾオキサゾール‐2‐イル)ピロリジン‐2R‐イルメ トキシ)フェニル〕‐2‐(2‐ベンゾイルフェニルアミノ)プロピオン酸 3‐〔4‐(1‐ベンゾオキサゾール‐2‐イル)ピロリジン‐2S‐イルメ トキシ)フェニル〕‐2‐(2‐ベンゾイルフェニルアミノ)プロピオン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(2‐シクロヘキサンカルボニルフェニルアミノ)プロピオン 酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(2‐ベンゾイルチオフェン‐3‐イルアミノ)プロピオン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐ベンジルプロピオン酸トリフルオロアセテート 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(2‐ブロモベンジル)プロピオン酸トリフルオロアセテート 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2(S)‐〔(4‐オキソ‐4H‐クロメン‐3‐カルボニル)ア ミノ〕プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチ ル‐2‐フェニルオキサゾール‐4‐イル)エトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(4‐クロロフェ ニル)チアゾール‐4‐イルメトキシ〕フェニル〕プロピオン酸 3‐〔4‐(2‐ベンゾイミダゾール‐1‐イルエトキシ)フェニル〕‐2‐ (2‐ベンゾイルフェニルアミノ)プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチ ル‐2‐(4‐メトキシ)フェニルオキサゾール‐4‐イル)エトキシ〕フェニ ル〕プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチ ル‐2‐(4‐フルオロ)フェニルオキサゾール‐4‐イル)エトキシ〕フェニ ル〕プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチ ル‐2‐(5‐メチルチエン‐2‐イル)オキサゾール‐4‐イル)エトキシ〕 フェニル〕プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチ ル‐1‐フェニル‐1H‐ピラゾール‐3‐イル)エトキシ〕フェニル〕プロピ オン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチ ル‐2‐ピペリジン‐1‐イルオキサゾール‐4‐イル)エトキシ〕フェニル〕 プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチ ル‐2‐モルホリン‐4‐イルチアゾール‐4‐イル)エトキシ〕フェニル〕プ ロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチ ル‐2‐(4‐ピリジル)チアゾール‐4‐イル)エトキシ〕フェニル〕プロピ オン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(2‐ジメ チルアミノ‐5‐メチルチアゾール‐4‐イル)エトキシ〕フェニル〕プロピオ ン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチ ル‐2‐(5‐メチルイソキサゾール‐3‐イル)チアゾール‐4‐イル)エト キシ〕フェニル〕プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐〔5‐メチ ル‐2‐(4‐メチル〔1,2,3〕チアジアゾール‐5‐イル)チアゾール‐ 4‐イル〕エトキシ〕フェニル〕プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐〔5‐メチ ル‐2‐(4‐メチルピペラジン‐1‐イル)チアゾール‐4‐イル〕エトキシ 〕フェニル〕プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐〔2‐(3 ‐ジメチルアミノプロピルアミノ)‐5‐メチルチアゾール-4‐イル〕エトキ シ〕フェニル〕プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐〔2‐(2 ‐メトキシエチルアミノ)‐5‐メチルチアゾール‐4‐イル〕エトキシ〕フェ ニル〕プロピオン酸 2‐〔1‐カルボキシ‐2‐〔4‐〔2‐(5‐メチル‐2‐フェニルチアゾ ール‐4‐イル)エトキシ〕フェニル〕エチルアミノ〕安息香酸メチルエステル 2‐〔1‐カルボキシ‐2‐〔4‐〔2‐(4‐クロロフェニルスルファニル )エトキシ〕フェニル〕エチルアミノ〕安息香酸メチルエステル 2‐〔1‐カルボキシ‐2‐〔4‐(1‐フェニルピロリジン‐2‐イルメト キシ)フェニル〕エチルアミノ〕安息香酸メチルエステル 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(2‐シクロペンタンカルボニルフェニルアミノ)プロピオン 酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(2‐シクロヘプタンカルボニルフェニルアミノ)プロピオン 酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(2‐シクロヘキサンカルボニル‐5‐フルオロフェニルアミ ノ)プロピオン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(4‐シクロヘキサンカルボニル‐2‐メチル‐2H‐ピラゾ ール‐3‐イルアミノ)プロピオン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(3‐ベンゾイルチオフェン‐2‐イルアミノ)プロピオン酸 2‐(2‐シクロヘキサンカルボニルフェニルアミノ)‐3‐〔4‐〔2‐( 5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エトキシ〕フェニル〕プロ ピオン酸 2‐(2‐シクロヘキサンカルボニルフェニルアミノ)‐3‐〔4‐〔2‐( 5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エトキシ〕フェニル〕プロ ピオン酸 3‐〔4‐(1‐ベンゾオキサゾール‐2‐イルピロリジン‐3‐イルオキシ )フェニル〕‐2‐(2‐ベンゾイルフェニルアミノ)プロピオン酸 3‐〔4‐〔2‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エト キシ〕フェニル〕‐2(S)‐〔2‐(ピリジン‐4‐カルボニル)フェニルア ミノ〕プロピオン酸 3‐〔4‐〔2‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エト キシ〕フェニル〕‐2(S)‐〔2‐(ピリジン‐N‐オキシド‐4‐カルボニ ル)フェニルアミノ〕プロピオン酸 3‐〔4‐〔2‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エト キシ〕フェニル〕‐2(S)‐〔2‐(ピリジン‐3‐カルボニル)フェニルア ミノ〕プロピオン酸 3‐〔4‐〔2‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エト キシ〕フェニル〕‐2(S)‐〔2‐(ピリジン‐N‐オキシド‐3‐カルボニ ル)フェニルアミノ〕プロピオン酸 2S‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチル‐ 3‐フェニルピラゾール-1‐イル)エトキシ〕フェニル〕プロピオン酸 2S‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐(1‐ピリジン‐2‐ ィルピロリジン‐2S‐イルメトキシ)フェニル〕プロピオン酸 2S‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(1‐メチル‐ 4‐フェニル‐1H‐イミダゾール‐2‐イル)エトキシ〕フェニル〕プロピオ ン酸 2S‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(3‐フラン‐ 2‐イル‐5‐メチルピラゾール‐1‐イル)エトキシ〕フェニル〕プロピオン 酸 2S‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチル‐ 3‐フェニル〔1,2,4〕トリアゾール‐1‐イル)エトキシ〕フェニル〕プ ロピオン酸 2S‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐2‐(3‐メトキシ メチル‐5‐メチル‐2‐フェニル‐3H‐イミダゾール‐4‐イル)エトキシ 〕フェニル〕プロピオン酸 2S‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチル‐ 2‐フェニル‐3H‐イミダゾール‐4‐イル)エトキシ〕フェニル〕プロピオ ン酸塩酸塩 2S‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチル‐ 2‐フェニルチアゾール‐4‐イル)エトキシ〕フェニル〕プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチ ル‐2‐(3‐メチルチエン‐2‐イル)オキサゾール‐4‐イル)エトキシ〕 フェニル〕プロピオン酸 2(S)‐〔2‐〔4‐〔2‐(5‐ニトロ‐2‐ピリジルオキシ)エトキシ 〕フェニル〕‐1‐メトキシカルボニルエチルアミノ〕安息香酸 2(S)‐〔2‐〔4‐〔2‐(5‐クロロ‐2‐ピリジルスルファニル)エ トキシ〕フェニル〕‐1‐メトキシカルボニルエチルアミノ〕安息香酸 2(S)‐〔2‐〔4‐〔2‐(N‐エチル‐2‐メチルトルイジノ)エトキ シ〕フェニル〕‐1‐メトキシカルボニルエチルアミノ〕安息香酸 3‐〔4‐(3‐ベンゾオキサゾール‐2‐イルチアゾリジン‐4(R)‐イ ルメトキシ)フェニル〕‐2(S)‐(2‐ベンゾイルフェニルアミノ)プロピ オン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(4‐トリフルオロメチルベンゾイル)フェニルアミノ 〕プロピオン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(2‐チオフェンカルボニル)フェニルアミノ〕プロピ オン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(3‐チオフェンカルボニル)フェニルアミノ〕プロピ オン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(3‐トリフルオロメチルベンゾイル)フェニルアミノ 〕プロピオン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(2‐トリフルオロメチルベンゾイル)フェニルアミノ 〕プロピオン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(3‐メトキシベンゾイル)フェニルアミノ〕プロピオ ン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(2‐メトキシベンゾイル)フェニルアミノ〕プロピオ ン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(3‐メチルベンゾイル)フェニルアミノ〕プロピオン 酸 2‐〔2‐(4‐ジメチルアミノメチルベンゾイル)フェニルアミノ〕‐3‐ 〔4‐〔2‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エトキシ〕 フェニル〕プロピオン酸塩酸塩 2‐〔2‐(4‐アミノメチルベンゾイル)フェニルアミノ〕‐3‐〔4‐〔 2‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エトキシ〕フェニル 〕プロピオン酸塩酸塩 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(2,6‐ジメチルベンゾイル)フェニルアミノ〕プロ ピオン酸 3‐〔2‐〔1‐カルボキシ‐2‐〔4‐〔2‐(5‐メチル‐2‐フェニル オキサゾール-4‐イル)エトキシ〕フェニル〕エチルアミノ〕ベンゾイル安息 香酸 2‐〔2‐(3‐ヒドロキシメチルベンゾイル)フェニルアミノ〕‐3‐〔4 ‐〔2‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エトキシ〕フェ ニル〕プロピオン酸 2‐〔2‐(3‐アミノメチルベンゾイル)フェニルアミノ〕‐3‐〔4‐〔 2‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エトキシ〕フェニル 〕プロピオン酸塩酸塩 2‐〔2‐(3‐ジメチルアミノメチルベンゾイル)フェニルアミノ〕‐3‐ 〔4‐〔2‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エトキシ〕 フェニル〕プロピオン酸塩酸塩 2(S)‐〔1‐カルボキシ‐2‐〔4‐〔2‐(5‐メチル‐2‐フェニル オキサゾール‐4‐イル)エトキシ〕フェニル〕エチルアミノ〕安息香酸メチル エステル 2(S)‐〔1‐カルボキシ‐2‐〔4‐〔2‐(5‐メチル‐2‐フェニル オキサゾール‐4‐イル)エトキシ〕フェニル〕エチルアミノ〕安息香酸2‐ア ミノエチルアミド塩酸塩 2(S)‐〔1‐カルボキシ‐2‐〔4‐〔2‐(5‐メチル‐2‐フェニル オキサゾール‐4‐イル)エトキシ〕フェニル〕エチルアミノ〕安息香酸3‐ア ミノプロピルアミド塩酸塩 2‐〔1‐カルボキシ‐2‐〔4‐〔2‐(5‐メチル‐2‐フェニルオキサ ゾール‐4‐イル)エトキシ〕フェニル〕エチルアミノ〕安息香酸メチルアミド 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(3‐ヒドロキシベンゾイル)フェニルアミノ〕プロピ オン酸 3‐〔4‐〔2‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エト キシ〕フェニル〕‐2‐〔2‐(4‐プロピルスルファモイルベンゾイル)フェ ニルアミノ〕プロピオン酸 2‐〔2‐(3‐アミノベンゾイル)フェニルアミノ〕‐3‐〔4‐〔2‐( 5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エトキシ〕フェニル〕プロ ピオン酸 2‐〔2‐(3‐メタンスルホニルアミノベンゾイル)フェニルアミノ〕‐3 ‐〔4‐〔2‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エトキシ 〕フェニル〕プロピオン酸 2‐〔2‐(3‐メトキシカルボニルアミノベンゾイル)フェニルアミノ〕‐ 3‐〔4‐〔2‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エトキ シ〕フェニル〕プロピオン酸 2‐〔2‐(3‐ヒドロキシベンゾイル)フェニルアミノ〕‐3‐〔4‐〔2 ‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エトキシ〕フェニル〕 プロピオン酸 2‐〔2‐(3‐カルバモイルメトキシベンゾイル)フェニルアミノ〕‐3‐ 〔4‐〔2‐(5‐メチル‐2‐フェニルオキサゾール‐4‐イル)エトキシ〕 フェニル〕プロピォン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチ ル‐2‐ピリジン‐4‐イルオキサゾール‐4‐イル)エトキシ〕フェニル〕プ ロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐〔5‐メチ ル‐2‐(4‐メチルピペラジン‐1‐イル)チアゾール‐4‐イル〕エトキシ )フェニル〕プロピオン酸塩酸塩 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐〔5‐メチ ル‐2‐(4‐tert‐ブトキシカルボニルピペラジン‐1‐イル)チアゾール‐ 4‐イル〕エトキシ〕フェニル〕プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチ ル‐2‐ピペラジン‐1‐イルチアゾール‐4‐イル)エトキシ〕フェニル〕プ ロピオン酸 (S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐〔5‐メチル ‐2‐(4‐メチルスルホニルピペラジン‐1‐イル)チアゾール‐4‐イル〕 エトキシ〕フェニル〕プロピオン酸 2(S)‐〔1‐カルボキシ‐2‐〔4‐〔2‐(4‐ジメチルアミノフェニ ル)エトキシ〕フェニル〕エチルアミノ〕安息香酸メチルエステル 2(S)‐〔1‐メトキシカルボキシ‐2‐〔4‐〔2‐〔5‐メチル‐2‐ (4‐メチルピペラジン‐1‐イル)チアゾール‐4‐イル〕エトキシ〕フェニ ル〕エチルアミノ〕安息香酸 2(S)‐〔1‐カルボキシ‐2‐〔4‐〔2‐(4‐クロロフェニル)エト キシ〕フェニル〕エチルアミノ〕安息香酸メチルエステル 2(S)‐〔1‐カルボキシ‐2‐〔4‐〔2‐(4‐トリフルオロメトキシ フェニル)エトキシ〕フェニル〕エチルアミノ〕安息香酸メチルエステル 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐3‐(4-ベンゾイルチエニルアミノ)プロピオン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(4‐ビフェニルカルボニル)フェニルアミノ〕プロピ オン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(4‐メトキシベンゾイル)フェニルアミノ〕プロピオ ン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(4‐メチルベンゾイル)フェニルアミノ〕プロピオン 酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐〔2‐(2‐メチルベンゾイル)フェニルアミノ〕プロピオン 酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(4‐クロロフェ ニル)エトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(4‐メチルチア ゾール‐5‐イル)エトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(4‐クロロフェ ニルスルファニル)エトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐(4‐イソプロピルベン ジルオキシ)フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐(4‐クロロベンジルオ キシ)フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔3‐(4‐メトキシフ ェニル)プロポキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(4‐ジメチルア ミノフェニル)エトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(4‐ブロモフェ ノキシ)エトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐ニトロピリ ジン‐2‐イルオキシ)エトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐ 2‐〔3‐(6‐メチ ルピリジン‐2‐イル)プロポキシ〕エトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐(2‐ピリジン‐3‐イ ルエトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(3‐メチル‐6 ‐オキソ‐6H‐ピリダジン‐1‐イル)エトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(4‐トリフルオロ メトキシフェニル)エトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(3‐シアノフェ ノキシ)エトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(6‐メトキシピ リジン‐2‐イルスルファニル)エトキシ〕フェニル〕プロピオン酸 2‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔1‐(4‐ニトロフェ ニル)ピロリジン‐2‐イルメトキシ)フェニル〕プロピオン酸 からなる群より選択される、請求項1に記載の化合物。 21. 2(S)‐〔1‐カルボキシ‐2‐〔4‐〔2‐(5‐メチル‐2‐ フェニルオキサゾール‐4‐イル)エトキシ〕フェニル〕エチルアミノ〕安息香 酸メチルエステル 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2(S)‐(2‐ベンゾイルフェニルアミノ)プロピオン酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(2‐シクロヘキサンカルボニルフェニルアミノ)プロピオン 酸 3‐〔4‐〔2‐(ベンゾオキサゾール‐2‐イルメチルアミノ)エトキシ〕 フェニル〕‐2‐(2‐ベンゾイルチオフェン‐3‐イルアミノ)プロピオン酸 2(S)‐〔1‐メトキシカルボニル‐2‐〔4‐〔2‐〔5‐メチル‐2‐ (4‐メチルピペラジン‐1‐イル)チアゾール‐4‐イル〕エトキシ〕フェニ ル〕エチルアミノ〕安息香酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(メチルピ リジン‐2‐イルアミノ)エトキシ〕フェニル〕プロピオン酸 2(S)‐(2‐ベンゾイルフェニルアミノ)‐3‐〔4‐〔2‐(5‐メチ ル‐2‐フェニルオキサゾール‐4‐イル)エトキシ〕フェニル〕プロピオン酸 並びにそれらの薬学上許容される塩および溶媒和物からなる群より選択される、 請求項20に記載の化合物。 22. 請求項1〜21のいずれか一項に記載された化合物またはその薬学上 許容される塩もしくは溶媒和物を薬学上許容されるキャリアと一緒に含んでなる 、医薬組成物。 23. 治療用の、請求項1〜21のいずれか一項に記載された化合物。 24. 請求項1〜21のいずれか一項に記載された化合物を投与することか らなる、PPAR‐γ媒介疾患または症状の治療または予防方法。 25. 請求項1〜21のいずれか一項に記載された化合物を投与することか らなる、血中グルコースを低下させる方法。 26. 請求項1〜21のいずれか一項に記載された化合物を投与することか らなる、高血糖症、脂血症、II型糖尿病、I型糖尿病、高トリグリセリド血症、 X症候群、インシュリン抵抗症、心不全、糖尿病性脂血症、高脂血症、高コレス テロール血症、高血圧、肥満、食欲不振大食症、神経性食欲不振および心血管疾 患、特にアテローム性動脈硬化症、の治療または予防方法。 27. PPAR‐γ媒介疾患の治療用薬剤の製造のための、請求項1〜21 のいずれか一項に記載された化合物の使用。 28. 低い血中グルコースレベルが必要とされる個体の治療用薬剤の製造に 関する、請求項1〜21のいずれか一項に記載された化合物の使用。 29. 高血糖症、脂血症、II型糖尿病、I型糖尿病、高トリグリセリド血症 、X症候群、インシュリン抵抗症、心不全、糖尿病性脂血症、高脂血症、高コレ ステロール血症、高血圧、肥満、食欲不振大食症、神経性食欲不振および心血管 疾患、特にアテローム性動脈硬化症、の治療用薬剤の製造に関する、請求項1〜 21のいずれか一項に記載された化合物の使用。 30. 式A‐B‐Xの化合物を下記式(II)の化合物 (上記式中A、B、Alk、R1およびZは請求項1に記載されたとおりであり 、BはC1-6アルキレンを含んでいて、Xは脱離基またはヒドロキシル基である )と反応させる工程を含んでなる、請求項1に記載された化合物の製造法。 31. Xがヒドロキシル基、ハライド、またはアルキル‐もしくはアリール スルホニルオキシ基であり、Aがフェニル、ピリジルまたはベンゾオキサゾリル であり、BがHet‐C1-6アルキレンであり、Zが ‐NH‐Y‐(C=O)‐T‐R5であって、ここでYは1以上のC1-3アルキル 基および/または1以上のハロゲン原子で場合により置換されたフェニルであり 、Tは結合または‐O‐であり、R5はC1-6アルキルまたはフェニル〔1以上の ハロゲン原子、C1-3アルキル、C1-3アルコキシ基、C0-3アルキレンNR9R10 (各R9およびR10は独立して水素、C1-3アルキル、‐SO2C1-3アルキル、‐ CO2C1-3アルキル、‐SO2NHC1-3アルキルである)、C0-3アルキレンC O2H、C0-3アルキレンCO2C1-3アルキ ルまたは‐OCH2C(O)NH2で場合により置換されている〕である、請求項 30に記載の方法。 32. R1が水素であり、Xがハライド、またはアルキル‐もしくはアリー ルスルホニルオキシ基である、請求項30または31に記載の方法。 33. A‐B‐Xおよび式(II)の化合物が以下である: (上記式中OMsはメシレート脱離基であり、R13はフェニルまたは‐OCH3 基である)、請求項32に記載の方法。 34. R1がC1-3アルキルであり、Xがヒドロキシル基である、請求項30 または31に記載の方法。 35. 反応が、Mitsunobu反応と、その後エステルの単離なしにアルキルエ ステル基から対応酸への加水分解を含んでなる、請求項34に記載の方法。 36. Mitsunobu反応が、トルエンを含んだ反応混合液中で行われる、請求 項35に記載の方法。 37. A‐B‐Xおよび式(II)の化合物が以下である: (上記式中R13はフェニルまたは‐OCH3基である)、請求項34〜36の いずれか一項に記載の方法。 38. 式(II)の化合物において、Zが以下であり: Zがである式(II)の化合物を最初に製造する工程、その後水素受容体の存在下にお いて脱水素触媒で脱水素させる工程により、式(II)の化合物が製造される、請 求項30または31に記載の方法。 39. 水素受容体が芳香族ニトロ化合物である、請求項38に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9604242.9A GB9604242D0 (en) | 1996-02-28 | 1996-02-28 | Chemical compounds |
GB9604242.9 | 1996-02-28 | ||
PCT/EP1997/000916 WO1997031907A1 (en) | 1996-02-28 | 1997-02-26 | Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000507216A true JP2000507216A (ja) | 2000-06-13 |
JP3255930B2 JP3255930B2 (ja) | 2002-02-12 |
Family
ID=10789571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53058697A Expired - Fee Related JP3255930B2 (ja) | 1996-02-28 | 1997-02-26 | PPAR―γに対するアゴニスト活性を有する置換4―ヒドロキシフェニルアルカン酸誘導体 |
Country Status (41)
Country | Link |
---|---|
US (1) | US6294580B1 (ja) |
EP (1) | EP0888317B1 (ja) |
JP (1) | JP3255930B2 (ja) |
KR (1) | KR100462730B1 (ja) |
CN (1) | CN1093124C (ja) |
AP (1) | AP780A (ja) |
AR (1) | AR011502A1 (ja) |
AT (1) | ATE205485T1 (ja) |
AU (1) | AU717699B2 (ja) |
BG (1) | BG102792A (ja) |
BR (1) | BR9707786B1 (ja) |
CA (1) | CA2247443C (ja) |
CY (1) | CY2319B1 (ja) |
CZ (1) | CZ295383B6 (ja) |
DE (1) | DE69706658T2 (ja) |
DK (1) | DK0888317T3 (ja) |
EA (1) | EA001403B1 (ja) |
EE (1) | EE9800288A (ja) |
ES (1) | ES2163125T3 (ja) |
GB (1) | GB9604242D0 (ja) |
GE (1) | GEP20012580B (ja) |
HK (1) | HK1015369A1 (ja) |
HR (1) | HRP970110B1 (ja) |
HU (1) | HUP0004845A3 (ja) |
ID (1) | ID15985A (ja) |
IL (1) | IL125796A (ja) |
IS (1) | IS1869B (ja) |
MY (1) | MY119425A (ja) |
NO (1) | NO311516B1 (ja) |
NZ (1) | NZ331381A (ja) |
OA (1) | OA10843A (ja) |
PE (1) | PE43098A1 (ja) |
PL (1) | PL191118B1 (ja) |
PT (1) | PT888317E (ja) |
RS (1) | RS49586B (ja) |
SI (1) | SI0888317T1 (ja) |
SK (1) | SK282753B6 (ja) |
TR (1) | TR199801707T2 (ja) |
UA (1) | UA58502C2 (ja) |
WO (1) | WO1997031907A1 (ja) |
ZA (1) | ZA971645B (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004518652A (ja) * | 2000-12-18 | 2004-06-24 | スミスクライン ビーチャム パブリック リミテッド カンパニー | 新規治療 |
JP2004277397A (ja) * | 2002-05-24 | 2004-10-07 | Takeda Chem Ind Ltd | 1,2−アゾール誘導体 |
JP2007527880A (ja) * | 2004-03-09 | 2007-10-04 | エフ.ホフマン−ラ ロシュ アーゲー | Ppar活性化剤としてのピラゾリルインドリル誘導体 |
JP2008509929A (ja) * | 2004-08-13 | 2008-04-03 | メタボレックス インコーポレーティッド | Pparの調節剤およびそれらの調製法 |
JP2008524166A (ja) * | 2004-12-20 | 2008-07-10 | アダムド エスピー.ゼット オー.オー. | 糖尿病の処置のための新規な3−フェニルプロピオン酸誘導体 |
JP2008239616A (ja) * | 2007-02-28 | 2008-10-09 | Iyaku Bunshi Sekkei Kenkyusho:Kk | Hdl上昇剤 |
WO2008139879A1 (ja) * | 2007-04-26 | 2008-11-20 | Pharmafrontier, Co., Ltd. | G蛋白質共役型レセプター抑制剤および医薬 |
JP2009138011A (ja) * | 2001-05-15 | 2009-06-25 | F Hoffmann La Roche Ag | 糖尿病の処置においてppar−アルファ及び−ガンマアクチベーターとして使用するためのカルボン酸置換オキサゾール誘導体 |
JP2009539888A (ja) * | 2006-06-13 | 2009-11-19 | 中国科学院上海薬物研究所 | 複素環非ヌクレオシド系化合物及びその調製方法、医薬組成物、並びにその抗ウィルス剤としての用途 |
JP2016518420A (ja) * | 2013-05-17 | 2016-06-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピロリジン誘導体、その医薬組成物及び使用 |
Families Citing this family (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0925063A4 (en) * | 1996-07-01 | 2000-12-27 | Lilly Co Eli | Blood-glucose-lowering and lipid-lowering compounds |
CZ53699A3 (cs) | 1996-08-19 | 1999-07-14 | Japan Tobacco Inc. | Deriváty propionové kyseliny a jejich použití |
EP1006794B1 (en) | 1997-03-12 | 2007-11-28 | Robert W. Esmond | A method for treating or preventing alzheimer's disease |
DE69815008T2 (de) * | 1997-09-19 | 2004-04-01 | Ssp Co., Ltd. | Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel |
EP1026149A4 (en) * | 1997-10-02 | 2004-12-01 | Sankyo Co | AMIDOCARBONSÄUREDERIVATE |
US6444816B1 (en) * | 1997-10-27 | 2002-09-03 | Dr. Reddy's Research Foundation | Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
US6200995B1 (en) | 1998-01-29 | 2001-03-13 | Tularik Inc. | PPAR-γ modulators |
EP1056714B1 (en) | 1998-02-26 | 2004-08-11 | Celltech Therapeutics Limited | Phenylalanine derivatives as inhibitors of alpha4 integrins |
GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
KR100388120B1 (ko) | 1998-05-11 | 2003-06-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 저혈당 및 저지질혈 활성을 갖는 옥시이미노알칸산 유도체 |
GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB9811969D0 (en) * | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
SE9801990D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl propionic acid derivatives and analogs |
MA26634A1 (fr) * | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
JP4533534B2 (ja) * | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | グリコーゲンシンターゼキナーゼ3のインヒビター |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
GB9817118D0 (en) | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
GB9821061D0 (en) * | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821222D0 (en) | 1998-09-30 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
US6589969B1 (en) | 1998-10-16 | 2003-07-08 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
JP2002532416A (ja) * | 1998-12-17 | 2002-10-02 | マインドセット・バイオファーマシューティカルズ・(ユーエスエイ)・インコーポレイテッド | 脳のグルコース利用の増進 |
US6204288B1 (en) | 1999-03-08 | 2001-03-20 | The University Of Mississippi | 1,2-dithiolane derivatives |
US6127394A (en) * | 1999-03-08 | 2000-10-03 | The University Of Mississippi | 1,2-Dithiolane derivatives |
IL145732A0 (en) * | 1999-04-06 | 2002-07-25 | Sankyo Co | α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
AU4465200A (en) * | 1999-04-16 | 2000-11-02 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
MXPA01010472A (es) * | 1999-04-16 | 2002-05-06 | Reddy Research Foundation | Formas polimorficas novedosas de un agente contra la diabetes; procedimiento para su preparacion y composiciones farmaceuticas que las contienen. |
US6528507B1 (en) | 1999-04-16 | 2003-03-04 | Dr. Reddy's Laboratories Limited | Polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
ATE299861T1 (de) * | 1999-04-19 | 2005-08-15 | Coelacanth Corp | Ppar-(gamma) agonisten zur behandlung von type ii diabetes |
JP2002542237A (ja) * | 1999-04-20 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 新規な化合物、それらの製造及び使用 |
US6972294B1 (en) | 1999-04-20 | 2005-12-06 | Novo Nordisk, A/S | Compounds, their preparation and use |
US6369055B1 (en) | 1999-04-20 | 2002-04-09 | Novo Nordisk A/S | Compounds, their preparation and use |
US7414128B2 (en) | 1999-04-20 | 2008-08-19 | Dr. Reddy's Laboratories, Limited | Crystalline R-guanidines, Arginine or (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H -phenoxazin-10-yl)ethoxy]phenyl}propanoate |
JP2002542218A (ja) * | 1999-04-20 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 新規な化合物、それらの製造および使用 |
US6274608B1 (en) | 1999-04-20 | 2001-08-14 | Novo Nordisk A/S | Compounds, their preparation and use |
WO2000063209A1 (en) * | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
CA2371757A1 (en) * | 1999-04-28 | 2000-11-09 | Dr. Reddy's Research Foundation | Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
CZ20013834A3 (cs) | 1999-04-28 | 2002-04-17 | Aventis Pharma Deutschland Gmbh | Deriváty kyselin se třemi arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
JP4618845B2 (ja) * | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体 |
GB9913782D0 (en) * | 1999-06-14 | 1999-08-11 | Smithkline Beecham Plc | Novel compounds |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
ES2437103T3 (es) * | 1999-06-30 | 2014-01-08 | Amgen Inc. | Compuestos para la modulacion de la actividad de PPAR gamma |
US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
AU7073400A (en) * | 1999-08-27 | 2001-03-26 | Eli Lilly And Company | Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
AU778282B2 (en) | 1999-09-17 | 2004-11-25 | Kyorin Pharmaceutical Co. Ltd. | O-anisamide derivatives |
TWI260321B (en) * | 1999-09-22 | 2006-08-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
EP1589006A1 (en) * | 1999-09-22 | 2005-10-26 | Bristol-Myers Squibb Company | Oxa- and thiazole derivatives useful as antidiabetics and antidiobesity agents |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
CN1215059C (zh) * | 1999-12-03 | 2005-08-17 | 京都药品工业株式会社 | 新的杂环化合物及其盐和它们的医药用途 |
SE9904415D0 (sv) * | 1999-12-03 | 1999-12-03 | Astra Ab | New process |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
JP4316787B2 (ja) * | 2000-01-11 | 2009-08-19 | 壽製薬株式会社 | エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、 |
JP2001261674A (ja) * | 2000-03-22 | 2001-09-26 | Mitsui Chemicals Inc | ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
EP1332132B1 (en) | 2000-04-17 | 2007-10-10 | UCB Pharma, S.A. | Enamine derivatives as cell adhesion molecules |
US6653332B2 (en) | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
FR2808798A1 (fr) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
JP2004502762A (ja) | 2000-07-07 | 2004-01-29 | セルテック アール アンド ディ リミテッド | 二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体 |
AU2001275724A1 (en) | 2000-08-02 | 2002-02-13 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
WO2002013864A1 (fr) * | 2000-08-16 | 2002-02-21 | Sankyo Company, Limited | Preparation medicinale de prevention et traitement du cancer |
MXPA03001558A (es) * | 2000-08-23 | 2003-06-06 | Lilly Co Eli | Agonistas del receptor activado del proliferador de peroxisoma. |
WO2002016332A1 (en) | 2000-08-23 | 2002-02-28 | Eli Lilly And Company | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
ATE368653T1 (de) | 2000-08-23 | 2007-08-15 | Lilly Co Eli | Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten |
IL156505A0 (en) * | 2000-12-25 | 2004-01-04 | Ono Pharmaceutical Co | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient |
WO2002051441A1 (fr) | 2000-12-26 | 2002-07-04 | Sankyo Company, Limited | Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline |
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
DK1392714T3 (da) | 2001-03-12 | 2006-01-09 | Intercept Pharmaceuticals Inc | Steroider som agonister for FXR |
US20040077689A1 (en) * | 2001-04-25 | 2004-04-22 | Yasuo Sugiyama | Abc expression promoters |
PL367676A1 (en) | 2001-05-29 | 2005-03-07 | Kyoto Pharmaceutical Industries, Ltd. | Novel heterocyclic derivatives and medicinal use thereof |
CZ20033450A3 (cs) | 2001-05-29 | 2004-05-12 | Kyotoápharmaceuticaláindustriesźáltd | Heterocyklická sloučenina a její lékařské použití |
DE10127126A1 (de) * | 2001-06-05 | 2002-12-19 | Forschungszentrum Juelich Gmbh | Geschützte Tyrosinderivate, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung von O-(2-[·18·F]-Fluorethyl)-L-tyrosin |
HUP0400268A2 (hu) | 2001-06-07 | 2004-07-28 | Eli Lilly And Co. | Peroxiszóma proliferátorral aktivált receptorokat (PPAR) módosító hatóanyagok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
BR0210190A (pt) * | 2001-06-07 | 2004-04-06 | Lilly Co Eli | Moduladores de receptores ativados de proliferador de peroxissomo |
EP1414806A1 (en) * | 2001-07-30 | 2004-05-06 | Novo Nordisk A/S | Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
US7067530B2 (en) | 2001-07-30 | 2006-06-27 | Novo Nordisk A/S | Compounds, their preparation and use |
JP2004536152A (ja) * | 2001-07-30 | 2004-12-02 | ノボ ノルディスク アクティーゼルスカブ | 新規ビニルn−(2−ベンゾイルフェニル)−l−チロシン誘導体及び抗糖尿病剤等へのそれらの使用 |
US20030171377A1 (en) * | 2001-08-29 | 2003-09-11 | Bigge Christopher Franklin | Antidiabetic agents |
TW200300681A (en) | 2001-11-12 | 2003-06-16 | Ono Pharmaceutical Co | Carboxylic acid derivative compound and medicament containing same as active ingredient |
BR0214437A (pt) | 2001-11-30 | 2004-10-13 | Lilly Co Eli | Composto, composição farmacêutica, métodos de modular um receptor ativado por proliferador de peroxissoma, de tratar e de prevenir a diabete melito, e de tratar a sìndrome x, e doenças cardiovasculares em um mamìfero, e, uso de um composto |
AU2002354460A1 (en) * | 2001-12-11 | 2003-07-09 | Sankyo Company, Limited | Medicinal composition |
US20050107450A1 (en) * | 2001-12-21 | 2005-05-19 | Brown Kathleen K. | Dosing regimen for ppar-gamma activators |
AU2002366980A1 (en) | 2002-01-17 | 2003-07-30 | Toaeiyo Ltd. | Halogenobenzyl aminopropionic acid derivatives |
CA2474353A1 (en) * | 2002-01-23 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Method for screening a drug ameliorating insulin resistance |
US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
US20060148858A1 (en) * | 2002-05-24 | 2006-07-06 | Tsuyoshi Maekawa | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity |
GB0214149D0 (en) * | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
PL374860A1 (en) | 2002-07-09 | 2005-11-14 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
PL375230A1 (en) * | 2002-07-09 | 2005-11-28 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
WO2004037248A2 (en) * | 2002-10-24 | 2004-05-06 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
AU2003277576A1 (en) * | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
US7268157B2 (en) * | 2002-11-26 | 2007-09-11 | Shenzhen Chipscreen Biosciences, Ltd. | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity |
US6653334B1 (en) | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
BRPI0407180A (pt) | 2003-02-14 | 2006-02-07 | Lilly Co Eli | Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto |
GB0303600D0 (en) * | 2003-02-17 | 2003-03-19 | Glaxo Group Ltd | Novel therapeutic method and compositions |
US20060142356A1 (en) * | 2003-02-17 | 2006-06-29 | Davis Adrian F | Novel therapeutic method and compositions for topical administration |
US20050059708A1 (en) * | 2003-05-13 | 2005-03-17 | Karel Pospisilik | Processes for making thiazolidinedione derivatives and compounds thereof |
KR100796093B1 (ko) | 2003-07-02 | 2008-01-21 | 에프. 호프만-라 로슈 아게 | 티아졸 고리로 치환된 인돌릴 유도체 및 ppar조절제로서 그의 용도 |
EP1658273B1 (en) * | 2003-08-20 | 2007-01-03 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
JP4754487B2 (ja) * | 2003-08-20 | 2011-08-24 | エミスフィアー テクノロジーズ インコーポレイテッド | グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤 |
US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
TW200526588A (en) * | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
EP1688138A4 (en) | 2003-11-26 | 2008-01-16 | Takeda Pharmaceutical | AGENT FOR REGULATING THE FUNCTION OF A RECEIVER |
WO2005061441A1 (en) * | 2003-12-15 | 2005-07-07 | Eli Lilly And Company | Selective peroxisome proliferator activated receptor modulators |
BRPI0418148A (pt) | 2003-12-25 | 2007-04-17 | Takeda Pharmaceutical | composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto |
WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
EP2712617B2 (en) | 2004-03-12 | 2020-11-18 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using Fxr ligands |
CN101048367A (zh) | 2004-07-30 | 2007-10-03 | 萨尔瓦特实验室股份有限公司 | 作为PPARγ调节剂的新的酪氨酸衍生物 |
BRPI0515015A (pt) * | 2004-08-11 | 2008-07-01 | Kyorin Seiyaku Kk | derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável |
PL372332A1 (pl) * | 2005-01-19 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
PL372356A1 (pl) | 2005-01-20 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
WO2006082495A1 (en) * | 2005-02-02 | 2006-08-10 | Ranbaxy Laboratories Limited | Peroxisome proliferator activated receptor modulators |
ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
EP1939189A4 (en) | 2005-08-26 | 2013-03-13 | Shionogi & Co | DERIVATIVE HAVING AGONIST ACTIVITY AGAINST PPAR |
MX2009002282A (es) | 2006-09-07 | 2009-03-20 | Nycomed Gmbh | Tratamiento de combinacion para diabetes mellitius. |
JP2010502719A (ja) | 2006-09-08 | 2010-01-28 | ロード アイランド ホスピタル | アルコール誘発性脳疾患の治療、予防および回復 |
JP5292310B2 (ja) | 2007-01-19 | 2013-09-18 | インターセプト ファーマシューティカルズ, インコーポレイテッド | Tgr5調節剤としての23−置換胆汁酸およびその使用方法 |
WO2008117982A1 (en) * | 2007-03-28 | 2008-10-02 | Crystal Genomics, Inc. | Heterocyclic carboxylic acid derivatives and pharmaceutical composition for inhibiting lipid accumulation containing same |
CN105250285B (zh) * | 2007-04-11 | 2019-09-06 | 奥默罗斯公司 | 预防和治疗成瘾的组合物和方法 |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
CA2963857A1 (en) | 2007-06-04 | 2008-12-11 | Ben-Gurion University Of The Negev Research And Development Authority | Tri-aryl compounds and compositions comprising the same |
CN105037476B (zh) | 2008-07-30 | 2018-06-12 | 英特塞普特医药品公司 | Tgr5调节剂及其使用方法 |
HUE039171T2 (hu) | 2008-11-19 | 2018-12-28 | Intercept Pharmaceuticals Inc | TGR5 modulátorok és azok alkalmazási eljárása |
BRPI1009141A2 (pt) | 2009-03-11 | 2016-03-08 | Omeros Corp | composições e métodos para profilaxia e tratamento de vícios |
US8581001B2 (en) | 2010-04-16 | 2013-11-12 | Codman & Shurtleff | Metformin-cysteine prodrug |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US20120094959A1 (en) | 2010-10-19 | 2012-04-19 | Bonnie Blazer-Yost | Treatment of cystic diseases |
MX365192B (es) * | 2012-06-19 | 2019-05-23 | Synbias Pharma Ag | Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. |
CA3028207A1 (en) | 2012-06-19 | 2013-12-27 | Intercept Pharmaceuticals, Inc. | Preparation, uses and solid forms of obeticholic acid |
US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
JP6657101B2 (ja) | 2013-11-05 | 2020-03-04 | ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ | 糖尿病及びそれから生じる疾患合併症の治療のための化合物 |
WO2016071727A1 (en) | 2014-11-04 | 2016-05-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the prevention and the treatment of rapidly progressive glomerulonephritis |
US9987255B2 (en) | 2014-12-19 | 2018-06-05 | Merck Sharp & Dohme Corp. | 5,5-bicyclic oxazole orexin receptor antagonists |
CN104744282A (zh) * | 2015-02-17 | 2015-07-01 | 南通恒盛精细化工有限公司 | 一种胰岛素增敏剂的制备工艺 |
WO2019224393A1 (en) * | 2018-05-25 | 2019-11-28 | University Of Copenhagen | Fenofibrate for reducing hypoglycemia in type 1 diabetes/lada |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
US4342771A (en) | 1981-01-02 | 1982-08-03 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
US4367234A (en) | 1980-07-28 | 1983-01-04 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
RU1473300C (ru) | 1987-06-01 | 1995-02-09 | Научно-производственное объединение "Витамины" | Способ получения 4-бензоиламино-3-оксотетрагидротиофена |
US5220023A (en) | 1989-07-18 | 1993-06-15 | Janssen Pharmaceutica N.V. | Glycine derivatives |
DE3941438A1 (de) | 1989-12-15 | 1991-06-20 | Hoechst Ag | Neue 2-substituierte 4-(3-alkyl-5-tert.-butyl-4-hydroxy-phenyl)-thiazole, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung |
US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
JPH07505647A (ja) | 1992-04-10 | 1995-06-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 複素環化合物および2型糖尿病の治療におけるそれらの使用 |
PL176885B1 (pl) | 1992-07-03 | 1999-08-31 | Smithkline Beecham Plc | Kompozycja farmaceutyczna |
US5232945A (en) * | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
GB9225386D0 (en) | 1992-12-04 | 1993-01-27 | Smithkline Beecham Plc | Novel compounds |
GB9311661D0 (en) * | 1993-06-05 | 1993-07-21 | Smithkline Beecham Plc | Novel compounds |
GB9311644D0 (en) | 1993-06-05 | 1993-07-21 | Smithkline Beecham Plc | Novel compounds |
SE9302332D0 (sv) | 1993-07-06 | 1993-07-06 | Ab Astra | New compounds |
GB9315148D0 (en) | 1993-07-22 | 1993-09-08 | Smithkline Beecham Plc | Novel compounds |
JPH08325264A (ja) * | 1995-05-31 | 1996-12-10 | Sumitomo Metal Ind Ltd | 新規2−芳香環置換−3−フェニルプロピオン酸またはアクリル酸誘導体 |
JPH08325263A (ja) * | 1995-05-31 | 1996-12-10 | Sumitomo Metal Ind Ltd | 新規2−アミノ−3−フェニルプロピオン酸誘導体 |
JPH08325564A (ja) | 1995-06-05 | 1996-12-10 | Nec Corp | 有機薄膜el素子 |
EP0925063A4 (en) * | 1996-07-01 | 2000-12-27 | Lilly Co Eli | Blood-glucose-lowering and lipid-lowering compounds |
-
1996
- 1996-02-28 GB GBGB9604242.9A patent/GB9604242D0/en active Pending
-
1997
- 1997-02-25 MY MYPI97000725A patent/MY119425A/en unknown
- 1997-02-26 CN CN97193988A patent/CN1093124C/zh not_active Expired - Fee Related
- 1997-02-26 NZ NZ331381A patent/NZ331381A/en not_active IP Right Cessation
- 1997-02-26 PE PE1997000137A patent/PE43098A1/es not_active Application Discontinuation
- 1997-02-26 HU HU0004845A patent/HUP0004845A3/hu unknown
- 1997-02-26 JP JP53058697A patent/JP3255930B2/ja not_active Expired - Fee Related
- 1997-02-26 ZA ZA9701645A patent/ZA971645B/xx unknown
- 1997-02-26 DK DK97906130T patent/DK0888317T3/da active
- 1997-02-26 DE DE69706658T patent/DE69706658T2/de not_active Expired - Lifetime
- 1997-02-26 CZ CZ19982750A patent/CZ295383B6/cs not_active IP Right Cessation
- 1997-02-26 EE EE9800288A patent/EE9800288A/xx unknown
- 1997-02-26 EA EA199800664A patent/EA001403B1/ru not_active IP Right Cessation
- 1997-02-26 KR KR10-1998-0706730A patent/KR100462730B1/ko not_active IP Right Cessation
- 1997-02-26 HR HR970110A patent/HRP970110B1/xx not_active IP Right Cessation
- 1997-02-26 PT PT97906130T patent/PT888317E/pt unknown
- 1997-02-26 AT AT97906130T patent/ATE205485T1/de not_active IP Right Cessation
- 1997-02-26 ES ES97906130T patent/ES2163125T3/es not_active Expired - Lifetime
- 1997-02-26 PL PL328871A patent/PL191118B1/pl not_active IP Right Cessation
- 1997-02-26 SK SK1163-98A patent/SK282753B6/sk not_active IP Right Cessation
- 1997-02-26 WO PCT/EP1997/000916 patent/WO1997031907A1/en active IP Right Grant
- 1997-02-26 TR TR1998/01707T patent/TR199801707T2/xx unknown
- 1997-02-26 IL IL12579697A patent/IL125796A/en not_active IP Right Cessation
- 1997-02-26 EP EP97906130A patent/EP0888317B1/en not_active Expired - Lifetime
- 1997-02-26 SI SI9730233T patent/SI0888317T1/xx unknown
- 1997-02-26 UA UA98084544A patent/UA58502C2/uk unknown
- 1997-02-26 BR BRPI9707786-0A patent/BR9707786B1/pt not_active IP Right Cessation
- 1997-02-26 US US09/125,750 patent/US6294580B1/en not_active Expired - Fee Related
- 1997-02-26 GE GEAP19974466A patent/GEP20012580B/en unknown
- 1997-02-26 AU AU20935/97A patent/AU717699B2/en not_active Ceased
- 1997-02-26 CA CA002247443A patent/CA2247443C/en not_active Expired - Fee Related
- 1997-02-27 AR ARP970100771A patent/AR011502A1/es active IP Right Grant
- 1997-02-27 ID IDP970584A patent/ID15985A/id unknown
- 1997-02-27 AP APAP/P/1997/000935A patent/AP780A/en active
-
1998
- 1998-08-12 IS IS4822A patent/IS1869B/is unknown
- 1998-08-25 OA OA9800148A patent/OA10843A/en unknown
- 1998-08-27 NO NO19983940A patent/NO311516B1/no not_active IP Right Cessation
- 1998-08-28 RS YUP-369/98A patent/RS49586B/sr unknown
- 1998-09-24 BG BG102792A patent/BG102792A/xx unknown
-
1999
- 1999-02-05 HK HK99100498A patent/HK1015369A1/xx not_active IP Right Cessation
-
2003
- 2003-03-12 CY CY0300026A patent/CY2319B1/xx unknown
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004518652A (ja) * | 2000-12-18 | 2004-06-24 | スミスクライン ビーチャム パブリック リミテッド カンパニー | 新規治療 |
JP2009138011A (ja) * | 2001-05-15 | 2009-06-25 | F Hoffmann La Roche Ag | 糖尿病の処置においてppar−アルファ及び−ガンマアクチベーターとして使用するためのカルボン酸置換オキサゾール誘導体 |
JP2004277397A (ja) * | 2002-05-24 | 2004-10-07 | Takeda Chem Ind Ltd | 1,2−アゾール誘導体 |
JP2007527880A (ja) * | 2004-03-09 | 2007-10-04 | エフ.ホフマン−ラ ロシュ アーゲー | Ppar活性化剤としてのピラゾリルインドリル誘導体 |
JP2008509929A (ja) * | 2004-08-13 | 2008-04-03 | メタボレックス インコーポレーティッド | Pparの調節剤およびそれらの調製法 |
JP2008524166A (ja) * | 2004-12-20 | 2008-07-10 | アダムド エスピー.ゼット オー.オー. | 糖尿病の処置のための新規な3−フェニルプロピオン酸誘導体 |
JP2009539888A (ja) * | 2006-06-13 | 2009-11-19 | 中国科学院上海薬物研究所 | 複素環非ヌクレオシド系化合物及びその調製方法、医薬組成物、並びにその抗ウィルス剤としての用途 |
JP2008239616A (ja) * | 2007-02-28 | 2008-10-09 | Iyaku Bunshi Sekkei Kenkyusho:Kk | Hdl上昇剤 |
WO2008139879A1 (ja) * | 2007-04-26 | 2008-11-20 | Pharmafrontier, Co., Ltd. | G蛋白質共役型レセプター抑制剤および医薬 |
JP2016518420A (ja) * | 2013-05-17 | 2016-06-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピロリジン誘導体、その医薬組成物及び使用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000507216A (ja) | PPAR―γに対するアゴニスト活性を有する置換4―ヒドロキシフェニルアルカン酸誘導体 | |
JP5305914B2 (ja) | オキサゾール化合物及び医薬組成物 | |
US6498174B1 (en) | Substituted oxazoles and thiazoles derivatives as hPPARγ and hPPARα activators | |
KR100620337B1 (ko) | 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제 | |
JP2000516593A (ja) | 糖尿病及び肥満症の治療に用いられる選択的β▲下3▼作動物質としての置換スルホンアミド | |
JP2001509166A (ja) | 糖尿病および肥満の治療のためのβ▲下3▼作動薬としてのチアゾールベンゼンスルホンアミド | |
WO2007085136A1 (fr) | Dérivés de 1,3-benzodioxolecyclopentène, procédé de préparation et applications médicales | |
JPH09512275A (ja) | 糖尿病および肥満の治療のための選択的β▲下3▼作用物質としての置換スルホンアミド | |
WO2002076959A1 (fr) | Derive heterocyclique a cinq membres d'acide alcanoique | |
JPWO2002046176A1 (ja) | ペルオキシソーム増殖剤応答性受容体の活性化剤 | |
JP2000515133A (ja) | 血糖降下性および脂質低下性の化合物 | |
JP2001525399A (ja) | 選択的β3アドレナリン作動性作動薬 | |
JP4986927B2 (ja) | 医薬 | |
RU2296759C2 (ru) | N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты) | |
JP7428833B2 (ja) | ヒストン脱アセチル化酵素6阻害剤としての1,3,4-オキサジアゾール誘導体化合物、およびそれを含む医薬組成物 | |
KR100248643B1 (ko) | 아릴 및 헤테로아릴 알콕시나프탈렌 유도체 | |
KR20050040746A (ko) | PPARγ와 PPARα의 활성을 항진시키는 신규화합물, 그것의 제조방법, 및 그것을 함유한 약제 조성물 | |
JPWO2005095364A1 (ja) | フェノキシ酢酸誘導体及びそれを用いた医薬 | |
JPH07101945A (ja) | 2,4−オキサゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物 | |
WO2006044961A1 (en) | Ppar-gamma modulatores |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081130 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081130 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091130 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101130 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101130 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111130 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111130 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121130 Year of fee payment: 11 |
|
LAPS | Cancellation because of no payment of annual fees |